Fed Regist. 2018 Jan 23;83(15):3071-5.
The Comprehensive Addiction and Recovery Act (CARA) of 2016, which became law on July 22, 2016, amended the Controlled Substances Act (CSA) to expand the categories of practitioners who may, under certain conditions on a temporary basis, dispense a narcotic drug in Schedule III, IV, or V for the purpose of maintenance treatment or detoxification treatment. Separately, the Department of Health and Human Services, by final rule effective August 8, 2016, increased to 275 the maximum number of patients that a practitioner may treat for opioid use disorder without being separately registered under the CSA for that purpose. The Drug Enforcement Administration (DEA) is hereby amending its regulations to incorporate these statutory and regulatory changes.
2016年的《综合成瘾与康复法案》（CARA）于2016年7月22日成为法律，修订了《管制物质法案》（CSA），以扩大在某些特定条件下可临时为维持治疗或戒毒治疗目的而配发附表III、IV或V类麻醉药品的从业者类别。另外，卫生与公众服务部通过2016年8月8日生效的最终规则，将从业者在无需根据CSA另行注册的情况下可治疗的阿片类物质使用障碍患者的最大数量提高到了275名。美国缉毒局（DEA）特此修订其法规以纳入这些法定和监管变更。
